Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ACAD

ACAD - ACADIA Pharmaceuticals Inc Stock Price, Fair Value and News

24.85USD-0.02 (-0.08%)Market Closed
Watchlist

Market Summary

USD24.85-0.02
Market Closed
-0.08%

ACAD Stock Price

View Fullscreen

ACAD RSI Chart

ACAD Valuation

Market Cap

4.1B

Price/Earnings (Trailing)

-27.42

Price/Sales (Trailing)

6.46

EV/EBITDA

-30.65

Price/Free Cashflow

-45.36

ACAD Price/Sales (Trailing)

ACAD Profitability

EBT Margin

-20.82%

Return on Equity

-41.09%

Return on Assets

-23.53%

Free Cashflow Yield

-2.2%

ACAD Fundamentals

ACAD Revenue

Revenue (TTM)

631.9M

Rev. Growth (Yr)

61.96%

Rev. Growth (Qtr)

28.12%

ACAD Earnings

Earnings (TTM)

-148.8M

Earnings Growth (Yr)

-139.77%

Earnings Growth (Qtr)

-6.0K%

Breaking Down ACAD Revenue

Last 7 days

-4.7%

Last 30 days

-12.6%

Last 90 days

9.9%

Trailing 12 Months

32.4%

How does ACAD drawdown profile look like?

ACAD Financial Health

Current Ratio

2.38

ACAD Investor Care

Shares Dilution (1Y)

1.39%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023520.2M550.9M631.9M0
2022493.1M512.4M511.5M517.2M
2021458.2M463.4M474.4M484.1M
2020366.2M393.1M419.1M441.8M
2019237.9M264.0M300.3M339.1M
2018158.5M185.1M207.8M223.8M
201740.2M63.0M93.3M124.9M
201600017.3M
20150000
2014758.0K335.0K110.0K120.0K
20134.9M4.7M1.5M1.1M
20122.1M2.2M5.1M4.9M
201132.1M22.1M12.1M2.1M
201015.3M24.3M33.2M42.1M
20090006.4M

Tracking the Latest Insider Buys and Sells of ACADIA Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 08, 2024
kim austin d.
sold
-17,676
29.96
-590
evp,general counsel, secretary
Jan 08, 2024
davis stephen
sold
-111,811
29.96
-3,732
ceo
Jan 08, 2024
teehan brendan
sold
-21,900
29.96
-731
evp, coo, head of commercial
Jan 06, 2024
teehan brendan
acquired
-
-
1,287
evp, coo, head of commercial
Jan 06, 2024
davis stephen
acquired
-
-
9,528
ceo
Jan 06, 2024
kim austin d.
acquired
-
-
1,634
evp,general counsel, secretary
Dec 15, 2023
kihara james
sold
-56,600
28.3
-2,000
principal accounting officer
Nov 24, 2023
garofalo elizabeth a.
gifted
-
-
-2,918
-
Nov 20, 2023
kihara james
sold
-44,940
22.64
-1,985
principal accounting officer
Nov 20, 2023
schneyer mark c.
sold
-115,645
22.64
-5,108
evp, chief financial officer

1–10 of 50

Which funds bought or sold ACAD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
new
-
25,342,000
25,342,000
0.41%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-83.21
-1,244,000
420,000
0.04%
Feb 16, 2024
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
added
66.64
496,040
825,957
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-0.99
53,142,000
162,140,000
0.02%
Feb 16, 2024
CIM INVESTMENT MANAGEMENT INC
unchanged
-
107,338
320,990
0.10%
Feb 15, 2024
Palo Alto Investors LP
added
0.16
25,306,500
75,443,200
6.80%
Feb 15, 2024
DAGCO, INC.
new
-
4,102
4,102
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
40.37
7,347,840
13,974,200
-%
Feb 15, 2024
State of Wyoming
added
443
220,691
251,513
0.05%
Feb 15, 2024
BARCLAYS PLC
added
59.62
6,330,000
10,859,000
-%

1–10 of 40

Are Funds Buying or Selling ACAD?

Are funds buying ACAD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACAD
No. of Funds

Unveiling ACADIA Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
rtw investments, lp
6.9%
11,253,551
SC 13G
Feb 13, 2024
vanguard group inc
8.16%
13,396,009
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
6.9%
11,409,218
SC 13G/A
May 24, 2023
baker bros. advisors lp
26.5%
43,084,280
SC 13D/A
Feb 14, 2023
price t rowe associates inc /md/
2.6%
4,279,254
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.20%
13,279,775
SC 13G/A
Feb 01, 2023
blackrock inc.
6.3%
10,258,738
SC 13G/A
Jan 17, 2023
baker bros. advisors lp
26.0%
42,163,470
SC 13D/A

Recent SEC filings of ACADIA Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
3
Insider Trading
Feb 08, 2024
4
Insider Trading
Jan 31, 2024
8-K
Current Report
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 09, 2024
4
Insider Trading
Jan 09, 2024
4
Insider Trading
Jan 09, 2024
4
Insider Trading

What is the Fair Value of ACAD?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to ACADIA Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

ACADIA Pharmaceuticals Inc News

Latest updates
Business Wire36 hours ago
Reuters.com15 Feb 202405:26 pm
StockNews.com13 Feb 202406:39 pm

ACADIA Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue28.1%211,699,000165,235,000118,462,000136,490,000130,714,000134,563,000115,468,000130,758,000131,612,000115,221,000106,554,000121,007,000120,577,000110,103,00090,068,00098,326,00094,586,00083,205,00062,959,00059,571,00058,305,000
Costs and Expenses66.1%269,475,000162,198,000172,046,000182,553,000161,580,000168,214,000228,484,000175,415,000146,913,000158,930,000173,326,000188,169,000206,476,000154,113,000179,583,000154,725,000140,007,000140,296,000150,593,000126,846,000119,576,000
  S&GA Expenses2.0%97,890,00095,968,000101,235,000104,402,00078,108,00089,901,00096,679,000105,912,00081,666,00096,789,000111,661,000120,752,00081,592,00084,344,000101,973,00091,871,00072,696,00067,981,00093,090,00074,271,00061,089,000
  R&D Expenses167.1%156,963,00058,771,00069,144,00075,738,00081,336,00075,646,000128,855,00066,942,00058,565,00056,935,00056,973,00062,116,000120,083,00064,295,00072,636,00057,520,00062,622,00067,320,00052,923,00048,183,00053,112,000
EBITDA Margin-8.8%-0.21-0.19-0.28-0.41-0.42-0.39-0.43-0.34-0.40-0.56-0.56-0.63---------
Income Taxes150.6%13,033,0005,200,000-1,900,000838,500800,000400,000485,000189,000-332,000473,00021,000417,000-199,000393,000-400,000-264,000365,000375,00014,000376,000
Earnings Before Taxes-927.0%-52,100,0006,300,000-44,939,000-40,836,500-26,415,000-33,600,000-112,600,000-42,905,000-14,789,000-43,398,000-66,427,000-66,343,000-84,859,000-41,748,000-88,023,000-52,636,000-42,242,000-54,576,000-84,929,000-65,478,000-61,762,000
EBT Margin-8.3%-0.21-0.19-0.28-0.41-0.42-0.40-0.43-0.35-0.40-0.56-0.57-0.64---------
Net Income-5950.6%-65,176,0001,114,000-43,021,000-41,725,000-27,183,000-34,011,000-113,056,000-43,094,000-14,457,000-43,871,000-66,448,000-66,760,000-84,660,000-42,141,000-88,023,000-53,036,000-41,978,000-54,941,000-85,304,000-65,492,000-62,138,000
Net Income Margin-17.1%-0.24-0.20-0.28-0.42-0.42-0.40-0.43-0.35-0.40-0.56-0.57-0.64---------
Free Cashflow-818.9%-58,955,0008,201,000-17,933,000-23,854,000-727,000-13,125,000-76,329,000-23,121,000-17,064,000-25,372,000-61,225,000-29,487,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-1.6%633643655588602613624700718724755783796760747783766461501540266
  Current Assets1.3%499493503508522533542618641646674718730736724760742437476526254
    Cash Equivalents-9.0%98.0010829111515514020514795.0026730432645231017319038574.0098.0013564.00
  Inventory---------14.0011.0010.0010.008.006.006.006.005.004.005.004.004.00
  Net PPE-6.0%5.005.006.006.007.007.008.008.009.009.0010.009.008.007.005.003.003.003.004.003.003.00
Liabilities9.5%27024728118717717817915915116017415614197.0010984.0076.0072.0083.0061.0043.00
  Current Liabilities11.5%21018822412611711812096.0088.0095.0010910692.0086.0010075.0068.0064.0075.0060.0042.00
Shareholder's Equity-8.5%362396374400426435445541567565582627655663638699689389418479223
  Retained Earnings-2.7%-2,476-2,411-2,412-2,369-2,327-2,300-2,266-2,153-2,110-2,096-2,052-1,985-1,918-1,834-1,792-1,704-1,651-1,609-1,554-1,468-1,403
  Additional Paid-In Capital1.1%2,8392,8082,7872,7712,7552,7362,7122,6952,6772,6612,6342,6132,5732,4962,4292,4032,3401,9971,9721,9481,627
Shares Outstanding0.4%164163162162162162161161161161160160---------
Float------1,700---2,500---4,600---2,200---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-818.9%-58,9558,201-17,933-23,854-727-13,125-76,329-23,120-17,064-25,327-60,149-27,488-22,793-36,883-49,002-29,707-18,851-38,397-64,175-39,079-42,280
  Share Based Compensation22.3%18,53915,15414,70514,41418,31220,51214,96312,88015,54622,00513,18421,19521,37219,50722,34819,85022,02320,42219,88320,40120,169
Cashflow From Investing117.6%34,110-194,283192,518-17,74815,441-55,797131,34571,549-156,321-17,20730,877-116,958152,994126,86529,608-209,1449,92310,62722,758-188,94931,784
Cashflow From Financing132.8%12,7515,4781,4661,6142873,8312,4674,3651,0665,0057,72618,12611,71547,4013,75443,058319,9674,6464,176300,603211

ACAD Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues    
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Total revenues$ 211,699$ 130,714$ 495,396$ 380,745
Operating expenses    
Type of Cost, Good or Service [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Cost of product sales$ 14,622$ 2,136$ 23,747$ 7,753
Research and development156,96381,336284,878285,837
Selling, general and administrative97,89078,108295,094264,688
Total operating expenses269,475161,580603,719558,278
Loss from operations(57,776)(30,866)(108,323)(177,533)
Interest income, net4,1252,29512,4752,980
Other income1,5082,1565,1091,999
Loss before income taxes(52,143)(26,415)(90,739)(172,554)
Income tax expense13,03376816,3441,696
Net loss$ (65,176)$ (27,183)$ (107,083)$ (174,250)
Net loss per common share, basic$ (0.4)$ (0.17)$ (0.65)$ (1.08)
Net loss per common share, diluted$ (0.4)$ (0.17)$ (0.65)$ (1.08)
Weighted average common shares outstanding, basic164,234161,852163,488161,580
Weighted average common shares outstanding, diluted164,234161,852163,488161,580

ACAD Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Assets  
Cash and cash equivalents$ 98,193$ 114,846
Investment securities, available-for-sale247,727301,977
Accounts receivable, net92,80262,195
Interest and other receivables1,730885
Inventory20,7686,636
Prepaid expenses37,95021,398
Total current assets499,170507,937
Property and equipment, net4,8846,021
Operating lease right-of-use assets50,75855,573
Intangible assets, net66,8550
Restricted cash5,7705,770
Long-term inventory4,6284,924
Other assets4757,587
Total assets632,540587,812
Liabilities and stockholders’ equity  
Accounts payable12,31012,746
Accrued liabilities197,293112,884
Total current liabilities209,603125,630
Operating lease liabilities48,10352,695
Other long-term liabilities12,6609,074
Total liabilities270,366187,399
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 225,000,000 shares authorized at September 30, 2023 and December 31, 2022; 163,968,949 shares and 162,064,872 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively1616
Additional paid-in capital2,839,1112,770,923
Accumulated deficit(2,476,634)(2,369,551)
Accumulated other comprehensive loss(319)(975)
Total stockholders’ equity362,174400,413
Total liabilities and stockholders’ equity$ 632,540$ 587,812
ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
 CEO
 WEBSITEacadia.com
 EMPLOYEES540

ACADIA Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for ACADIA Pharmaceuticals Inc? What does ACAD stand for in stocks?

ACAD is the stock ticker symbol of ACADIA Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ACADIA Pharmaceuticals Inc (ACAD)?

As of Thu Feb 22 2024, market cap of ACADIA Pharmaceuticals Inc is 4.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers. The fair value of ACADIA Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ACADIA Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACAD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ACADIA Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACAD is over valued or under valued. Whether ACADIA Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ACADIA Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACAD.

What is ACADIA Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ACAD's PE ratio (Price to Earnings) is -27.42 and Price to Sales (PS) ratio is 6.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACAD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ACADIA Pharmaceuticals Inc's stock?

In the past 10 years, ACADIA Pharmaceuticals Inc has provided 0.005 (multiply by 100 for percentage) rate of return.